Preclinical evaluation of colon-targeted nanoparticles containing Commiphora leptophloeos extract for treating inflammatory bowel diseases and colitis-associated colorectal cancer.

Crohn's disease and ulcerative colitis are inflammatory bowel disease, characterized by chronic inflammation, which is an important risk factor for the development of colitis-associated colorectal cancer. Therefore, this approach aims to evaluate the impact of the administration of Commiphora leptophloeos leaf extract free or in nanoparticles (NPE) in murine model of colitis induced by sodium dextran sulfate (DSS) and colorectal cancer caused by azoxymethane/DSS. The produced NPE exhibited physicochemical properties suitable for the in vivo tests, as particle size less than 100 nm, polydispersity index of about 0.13, and zeta potential close to -20 with, with high entrapment efficiency. Its use significantly reduced the effective dose, from 400 mg/kg with the free extract to only 4 mg/kg. The results showed that the free extract and NPE significantly improved the disease activity index, the regulation of markers involved in the initiation of the intestinal inflammatory cascade, Tlr2/4, Jnk1/2, Cox-2 and consequently in the control of inflammatory cytokines, Il-1β, Il-6 and Il-17. Additionally, both free extract or incorporated into nanoparticles showed antitumor activity, acting on important signaling pathways of carcinogenesis, regulating Tp53, Ctnnb1, Bax, and Bcl-2, reducing the colonoscopic index and tumor volume, and recovering alterations in the intestinal microbiota, with an increase in the genus Akkermansia muciniphila. In conclusion, the pharmacological effect of C. leptophloeos extract was enhanced by incorporating it into nanoparticles, which facilitated the targeted delivery of bioactive components and reduced the required dose, offering a novel and effective alternative for the treatment of chronic inflammatory bowel diseases.